PICOSSIDE (0.4.1)
Approved for use through 07/13/2006 (0.40) 054-030.

U.S. Peletra att (1/stekmad 01/sq. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a volution contain named to

	Application Number		10595283	
NEODIATION DIOCI COURT	Filing Date		2004-09-16	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Boca		ing QIU	
( Not for submission under 37 CFR 1.99)	Art Unit			
The constant and the service of the constant and the cons	Examiner Name			
	Attorney Docket Numb	er	305832-00124	

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan
	1	6028877	A	2000-02-22	NEC Corporation			
	2	4794611	A1	1988-12-27	Canon KK			
	3	5923689	А	1999-07-13	Su et al.			
	4	5815521	А	1998-09-29	Vakhshoori et al.			
If you wis	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns, nt Passag Appear	Lines where ges or Relevan
	1	20010028668	A1	2001-10-11	Fukunaga et al.			
	2	20040047378	A1	2004-03-11	Erbert et al.			
If you wis	h to ac	dd additional U.S. Publis	hed Ap	plication citation	n information please click the Ad	d button	Add	
					TENT DOCUMENTS		Remove	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595283
iling Date		2004-09-16
irst Named Inventor Boca		ng QIU
Art Unit		
Examiner Name		
Attorney Docket Number		305832-00124

	_							_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Τs
	1	61-156788	JP	A1			translation of abstract only	¥
If you wish	h to a	dd additional Foreign F	Patent Documer	nt citation	information p	lease click the Add butto	n Add	
			NON-PAT	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		mal, serial, syn	nposium,	catalog, etc),	the article (when approp date, pages(s), volume-i		Τs
	1					eam divergence emitting at ast 2, 2001), Great Britain	t 808 <b>nm</b> ",	
	2					tapered laser arrays at 980 San Francisco, CA, May 3		Е
	3					ompensated InGaAs/GaAs May 23, 1996, pp. 1007-100		
	4		S COMMUNICAT	TIONS, Vo		ormance of an InGaAsP as; , October 1, 2002, pp. 289-		
	5		ANNUAL MEETIN	NG OF TH		es: thin p-clad and low dive S AND ELECTRO-OPTICS		
	6					ergence with integrated opt ONICS, Vol. 5, No. 3, May		_
	7	EUROPEAN PATENT April 2006	OFFICE acting a	is the IPS/	, Written Opinio	on in Applin. No. PCT/GB20	004/003959, issued 18	

If you wish to add additional non-patent literature document citation information please click the Add button Add

Application Number		10595283	
Filing Date		2004-09-16	
First Named Inventor Bocang QIU		ng QIU	
Art Unit			
Examiner Name			
Attorney Docket Number		305832-00124	
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Boca Art Unit Examiner Name	

EARNINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if	reference considered, whether or not citation is in conforma	nce with MPEP 609	Draw line through a			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kin Codes of USPTO Patent Documents at year LISPTO,GOV or MPEP 901.6. Firster office that issued to document, by the ho-letter code (WIPO Standard ST3.3 For Juapense plateful accounted), the validation of the year of the Proprior mater procedule the serial number of the plateful accounted. If Anni of document by the appropriate symbols as exclusived on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English language translation is attached.

# | Application Number | 1056;2623 | Filing Date | 2004:09-16 | Filing Date |

### Attorney Docket Number 3

305832,00124


That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, See 37 CPR 1.97(e/t1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(vic).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jefferson Perkins/	Date (YYYY-MM-DD)	2006-05-25
Name/Print	Jefferson Perkins	Registration Number	31407

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.